Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: TAZORAC

« Back to Dashboard

Summary for Tradename: TAZORAC

Patents:2
Applicants:1
NDAs:2
Suppliers: see list2

Pharmacology for Tradename: TAZORAC

Ingredient-typeRetinoids
Drug ClassRetinoid

Clinical Trials for: TAZORAC

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
Status: Recruiting Condition: Acne Vulgaris

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
Status: Recruiting Condition: Plaque Psoriasis

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
Status: Completed Condition: Acne Vulgaris

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails
Status: Completed Condition: Brittle Nails

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
Status: Recruiting Condition: Acne Vulgaris

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
Status: Completed Condition: Acne Vulgaris

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Status: Recruiting Condition: Cutaneous T-Cell Lymphoma

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
Status: Completed Condition: Acne Vulgaris

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184Sep 29, 2000RXYes<disabled><disabled>
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600Jun 13, 1997RXYes6,258,830<disabled><disabled>
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600Jun 13, 1997RXYes5,914,334<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc